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ABSTRACT
Objective: Coronavirus disease 2019 (COVID-19) has caused rapid and drastic changes 
in cancer management. The Italian Society of Gynecology and Obstetrics (SIGO), and 
the Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) 
promoted a national survey aiming to evaluate the impact of COVID-19 on clinical activity of 
gynecologist oncologists and to assess the implementation of containment measures against 
COVID-19 diffusion.
Methods: The survey consisted of a self-administered, anonymous, online questionnaire. The 
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survey was sent via email to all the members of the SIGO, and MITO groups on April 7, 2020, 
and was closed on April 20, 2020.
Results: Overall, 604 participants completed the questionnaire with a response-rate of 
70%. The results of this survey suggest that gynecologic oncology units had set a proactive 
approach to COVID-19 outbreak. Triage methods were adopted in order to minimize 
in-hospital diffusion of COVID-19. Only 38% of gynecologic surgeons were concerned 
about COVID-19 outbreak. Although 73% of the participants stated that COVID-19 has 
not significantly modified their everyday practice, 21% declared a decrease of the use of 
laparoscopy in favor of open surgery (19%). However, less than 50% of surgeons adopted 
specific protection against COVID-19. Additionally, responders suggested to delay cancer 
treatment (10%–15%), and to perform less radical surgical procedures (20%–25%) during 
COVID-19 pandemic.
Conclusions: National guidelines should be implemented to further promote the safety of 
patients and health care providers. International cooperation is of paramount importance, 
as heavily affected nations can serve as an example to find out ways to safely preserve clinical 
activity during the COVID-19 outbreak.
Keywords: Surgical Oncology; Health Care Surveys; COVID-19; SARS-CoV-2 Infection
INTRODUCTION
Coronaviruses (CoVs) are a large family of single-stranded RNA viruses [1]. In the past, 6 
types of CoVs have been identified as human-susceptible viruses, among which 2 α-CoVs 
(HCoV-229E and HCoV-NL63), and 2 β-CoVs (HCoV-HKU1 and HCoV-OC43) have low 
pathogenicity and cause mild respiratory symptoms. Other types (ie SARS-CoV and MERS-
CoV) lead to severe and potentially life-threatening respiratory tract infection [2].
The novel respiratory coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-
CoV-2) disease (coronavirus disease 2019; COVID-19) has been spreading in Europe and the 
United States by early 2020 [1]. Though the mortality rate of COVID-19 is much lower than 
that of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) (i.e., SARS of 2003), its 
transmission has been significantly greater, with a significant increase in the crude number 
of deaths [1,2].
The COVID-19 pandemic has dramatically changed our everyday life, keeping individuals in 
their homes all over the world. Medical practice has changed, as well. COVID-19 threatens 
to curtail patient access to evidence-based treatment. COVID-19 is testing our health care 
system. Several guidelines suggested avoiding unnecessary treatments during COVID-19 
outbreak [3,4]. The World Health Organization recommended strengthening the health 
systems and reorganize service delivery to respond to COVID-19 while maintaining 
essential core services across the continuum of care, especially in the field of oncology [5]. 
However, health care system resources are limited, and COVID-19 is directly impacting on 
our practice. The present situation requires growing resources for the treatment of infected 
patients, but patients without COVID-19 infection are not less important. In the field of 
gynecologic oncology, COVID-19 directly impacts on patients with cancer, who are at high 
risk of infections due to several predisposing factors [6]. Indirectly, COVID-19 impacts on 
our ability to treat patients. In fact, not all oncologic procedures can be delayed without 
compromising the efficacy of treatment itself.
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In Italy, the number of COVID-19 cases is rising day after day, even though the 
implementation of drastic national containment [7]. Almost every hospital was reorganized 
in order to meet the needs of patients with COVID-19. New areas and new intensive care 
units were set up. As a result, all elective activities were postponed or cancelled. A dedicated 
pathway was created in order to guarantee access in case of non-deferrable cases, including 
cancer management. Hospitals were classified into 2 main categories: 1) dedicated hubs for 
highly specialized treatments (including cancer treatment) named COVID-19-free HUBs and 
2) spoke for treatment of patients with COVID-19 [4].
To date, evidence on the diffusion and management of COVID-19 in gynecologic oncologic 
patients is scant. This situation has led gynecologic oncologists to join forces, with the aim 
to find a way not to compromise patients' care and to preserve the safety of health care 
providers. In Italy, 2 main societies promote working and research activities in gynecologic 
oncology on a national basis: the Italian Society of Gynecology and Obstetrics (SIGO – 
Società Italiana di Ginecologia Ostetricia), and the Multicenter Italian Trials in Ovarian 
cancer and gynecologic malignancies (MITO). Altogether these societies promoted a 
national survey aiming to evaluate the impact of COVID-19 on clinical activity and the 
implementation of containment measures of COVID-19 diffusion. Here, we present the 
results of this survey, providing an overview of the impact of COVID-19 on gynecologic 
oncology practice and methods applied to improve the safety of health care providers.
MATERIALS AND METHODS
The study protocol was approved by Institutional Review Board of the Fondazione IRCCS 
Istituto Nazionale dei Tumori. The SIGO, and MITO groups approved this investigation. 
Thorough a national survey, they aimed to assess changing in gynecological oncologic 
practice in Italy, during COVID-19 outbreak. The survey consisted of a self-administered, 
anonymous, online questionnaire (Supplementary Data 1). The survey was sent via email to 
all the members of the SIGO, and MITO groups on April 7, 2020, and was closed on April 20, 
2020. Supplementary Fig. 1 shows the status of COVID-19 outbreak in Italy during the period 
from April 7 to April 20.
The research center developed the survey under the supervision of the first and last authors. 
A dedicated team of expert and certificated statistics of the Fondazione IRCCS Istituto 
Nazionale dei Tumori evaluated the data and performed the statistical analysis. Before 
starting, the survey was tested in a selected group of ten physicians working in the setting 
of gynecologic oncology. No technical issues occurred, and the survey was completed by 
all physicians (their responses were not included in the results of the survey). Therefore, 
the research center sent individualized emails to SIGO, and MITO members, such that 
each member was assigned a unique survey link that allowed completing the survey only 
once. The use of the unique link allowed our research center to send 3 reminder emails 
to non-respondents. The survey was designed following the recommendation provided 
by the Questionnaire Design, Development, Evaluation, and Testing (QDET2), the World 
Association for Public Opinion Research (WAPOR), and the American Association for Public 
Opinion Research (AAPOR) [8-10]. The survey was in English and was not translated in 
Italian. The intended population included physicians working in the field of gynecologic 
oncologists (i.e. surgeons, medical oncologists, general gynecologists, and radiation 
oncologists) currently affiliated with the SIGO, and MITO groups at the time of the 
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survey. The primary aim of the survey was to assess the impact of COVID-19 in the field of 
gynecologic oncology. Specifically, the survey included a total of 45 questions, which were 
divided into 6 sections: the first section assessed the personal characteristics of responders 
(e.g., age, role, working setting, activity/patients' volume). The second section included 
questions related to the impact of COVID-19 on gynecologic oncology practice. The third 
section contained questions related to the triage procedures and protective measures adopted 
in the hospital against COVID-19. The fourth section addressed possible concerns related 
to surgery and methods adopted to protect health care providers. The fifth section included 
questions related to changes in the management of ovarian, endometrial and cervical cancer 
after COVID-19 outbreak. The last section contained questions related to the way COVID-19 
has impacted patients' follow-up schedules and their inclusion in clinical trials.
1. Statistical analysis
Basic descriptive statistics were used to describe the results. Results are reported as 
frequency and percentages and mean±standard deviation (SD), when appropriate. For 
analytic purposes, participants were classified into 2 main categories: physician working in 
a COVID-free hub or general hospital treating also patients with COVID-19. Additionally, 
results were classified on the basis of the role of responders (i.e., gynecologic surgeons, 
oncologists, radiation oncologists, and general gynecologists). Comparisons among 
respondents were evaluated with the Fisher's exact test or χ2 test. Differences in categorical 
variables were analyzed using the Fisher's exact test. Odds ratio (OR) and 95% confidence 
intervals (CIs) were calculated for each comparison. The t-test and Mann-Whitney test were 
used to compare continuous variables as appropriate. All calculated p-values were 2-sided; 
p-values <0.05 were considered statistically significant. Statistical analysis was performed 
with GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA) and IBM-
Microsoft SPSS version 20.0 (SPSS Statistics; International Business Machines Corporation 
[IBM], Armonk, NY, USA) for Mac.
RESULTS
Over the 14 days' study period, the survey was sent via email to 860 participants working 
in the setting of gynecologic oncology in Italy. Overall, 604 participants completed the 
questionnaire with a response-rate of 70%. The median time for questionnaire competition 
was 7 minutes. Among those who responded, 519 completed the questionnaire (86%). Age 
distribution of responders was <35, 35–50, 50–65, and >65 years of age in 24%, 33%, 35% and 
8%, respectively. The baseline characteristics of responders are displayed in Supplementary 
Fig. 2. Responders were classified as surgeons, medical oncologists, radiation oncologists 
and general gynecologists in 43%, 12%, 3%, and 33% of cases, respectively. Additionally, 
9% were classified as “other,” including residents in obstetrics and gynecology. Overall, 
205 responders (34%) belonged to COVID-free hubs, and 76% declared they feel adequately 
informed about COVID-19. However, on a scale between 0 (no risk) and 100 (maximum risk), 
the mean perceived risk for COVID-19 was 65±9. These data are presented in Supplementary 
Fig. 3. We observed that results of the survey in term of baseline characteristics of 
participants and response were not influenced by time of response (first vs. second week) and 
the affiliation (SIGO vs. MITO).
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1. Triage methods
Triage methods for patients admitted for surgery, chemotherapy, and radiotherapy 
procedures are shown in Supplementary Fig. 4. The most adopted method for triaging 
patients was the evaluation of patient's anamnestic data (e.g., history of fever, respiratory 
symptoms, exposure to COVID-19 case). SARS-CoV-2 rhino-pharyngeal swabs were adopted 
in 50%, 20%, and 20% as triage methods for patients admitted for surgery, chemotherapy, 
and radiotherapy procedures, respectively. Serology for SARS-CoV-2 immunoglobulins 
(immunoglobulin [Ig] M and IgG) was performed in 7%, 4%, and 4% of patients admitted for 
surgery, chemotherapy, and radiotherapy procedures, respectively. Low dose basal CT scan 
of the thorax was used in patients admitted for surgery, chemotherapy, and radiotherapy, in 
13%, 5%, and 3% of cases, respectively. Fig. 1 shows differences in terms of triage methods 
on the basis of the participants' role (surgeons, oncologist, radiation oncologist, and general 
gynecologist) and type of hospital (COVID-free HUB vs. other). Surgeons and general 
gynecologists adopted similar triage methods. In comparison to those latter, oncologists and 
radiation oncologists were more likely to avoid the use of CT scan of the thorax (p=0.060, χ2 
test) and swabs for COVID-19 (p<0.001, χ2 test). No difference in the adoption of serologic 
tests were observed (p=0.677, χ2 test). Triage methods stratified by surgical volume are 
reported in Supplementary Fig. 5 participants rated the use of “anamnestic data” as the best 
triage method, followed by swabs, IgM/IgG dosing, Chest X-ray, low-dose chest CT scan, and 
blood exams (Supplementary Fig. 6).
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Triage methods stratified by type of hospital
(COVID-free HUB vs. others)
Q17: COVID-free HUB
(e.g., cancer center)








Yes, using dosage of IgG/IgM for COVID-19
Yes, using specific swab for COVID-19
Yes, using blood test (e.g., complete blood counts, C-reactive protein)
Yes, using CT scan of the chest
Yes, using chest X-ray
Yes, using anamnestic data
(e.g., history of fever, cough, exposure to COVID-19 case)
No
Triage methods stratified by role of participants
Q6: Gynecologic
surgeon









Yes, using dosage of IgG/IgM for COVID-19
Yes, using specific swab for COVID-19
Yes, using blood test (e.g., complete blood counts, C-reactive protein)
Yes, using CT scan of the chest
Yes, using chest X-ray
Yes, using anamnestic data
(e.g., history of fever, cough, exposure to COVID-19 case)
No
Fig. 1. Triage methods. 
COVID, coronavirus disease; CT, computed tomography; Ig, immunoglobulin.
2. Impact of COVID-19 on surgical practice
Considering surgical procedures, 98 gynecologic surgeons (38%) declared that they are not 
concerned during the present COVID-19 outbreak. However, they stated to be concerned 
about performing laparoscopy, robotic-assisted surgery, open abdominal and vaginal surgery 
in 44%, 14%, 34%, and 13% of cases, respectively (multiple answers allowed). On a scale 
between 0 (no concern) and 100 (maximum concern), gynecologic surgeons rated the mean 
concern of performing laparoscopy as 42±31. Although 73% of the participants stated that 
COVID-19 has not significantly modified their everyday practice, 21% declared a decrease 
of the use of laparoscopy in favor of open (19%) and vaginal (2%) surgery. Interestingly, 
about 5% of the participants stated that the use of laparoscopic surgery has increased 
during the COVID-19 outbreak These data, also stratified by surgical volume are reported in 
Supplementary Fig. 7.
Surgeons adopted specific protections during open abdominal and laparoscopic surgery in 
59% and 51% of cases, respectively. Respirator masks were routinely used by 33%, and 35% 
of surgeons performing open surgery and laparoscopy, respectively. In case of laparoscopic 
procedure, smoke filters were adopted by 14% the responders. Table 1 shows the specific 
protection adopted during open abdominal and laparoscopic procedures. Fig. 2 reports 
differences in protection adopted by surgeons during laparoscopic procedures on the base 
of their setting (i.e., COVID-free HUBs vs. other centers). Supplementary Fig. 8 displayed 
specific protection used during laparoscopic procedures classified by surgical volume. No 
statistical difference existed in terms of protection used between COVID-free HUBs vs. other 
centers (p>0.200). Of note, surgeons working in COVID-free HUBs and other centers did not 
adopt specific protections in 47% and 50% of cases, respectively (p=0.962, Fisher's exact test).
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Table 1. Protection adopted during surgery
Variables Frequency
Changes in surgical approaches during COVID-19 outbreak 19.08%
Laparoscopic surgery decrease in favor of open surgery 2.29%
Laparoscopic surgery decrease in favor of vaginal surgery 0.38%
Laparoscopic surgery decrease in favor of robotic-assisted surgery 4.96%
Laparoscopic surgery increase 72.52%
Other (specify) 3.05%
Protections used during open abdominal procedures
No specific protections (surgical mask, gloves and apron) 45.59%
Face shield (full face protection) 28.35%
Eye goggles (eye protection) 41.00%
N95 respirators 6.51%
FFP3 respirator masks 18.01%
Other respirators that offer a high level of protection 8.81%
Other (specify) 3.07%
Protections used during laparoscopic procedures
No specific protection (surgical mask, gloves and apron) 48.85%
Face shield (full face protection) 22.52%
Eye goggles (eye protection) 38.17%
N95 respirators 7.63%
FFP3 respirator masks 19.85%
Other respirators that offer a high level of protection 7.63%
Laparoscopic smoke filtration filters 14.12%
Other (specify) 1.91%
COVID-19, coronavirus disease 2019.
3. Impact of COVID-19 on gynecologic cancers
Evaluating the impact of COVID-19 in gynecologic oncology practice, we observed that on 
a scale between 0 (no concern/impact) and 100 (maximum concern/impact), the mean±SD 
concern rate was 70±14. Similarly, responders rated as 70±15 the impact of COVID-19 in 
gynecologic oncology practice. Responders rated the impact of COVID-19 on the quality 
of care of gynecologic oncology patients as 46±18. Specifically, the impact of COVID-19 
on the quality of care of patients needing surgery, chemotherapy, and radiotherapy was 
rated as 48±5, 34±30, and 32±10, respectively. Considering different types of gynecological 
cancers, responders rated that the negative impact of COVID-19 to early-stage ovarian cancer, 
advanced-stage ovarian cancer, endometrial cancer, and cervical cancer was 27±20, 35±19, 
29±8, and 27±9, respectively. Survey participants evaluated how COVID-19 outbreak impacted 
on the current clinical management of ovarian (Fig. 3), endometrial, and cervical cancer 
(Table 2). Considering patients with ovarian cancer, the preferred treatment modalities 
of patients with advanced but potentially resectable disease were diagnostic laparoscopy 
followed by cytoreduction in case of low burden of disease (rating: 4.31), cytoreduction via 
open surgery (rating: 4.24), diagnostic laparoscopy followed by cytoreduction even in case 
of high burden of disease (rating: 4.10), diagnostic laparoscopy followed by neoadjuvant 
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Specific protection adopted during laparoscopic
procedures COVID-free HUBs vs. other centers
Q17: COVID-free HUB
(e.g., cancer center)








Laparoscopic smoke filtration filters
Other respirators that offer a high level of protection
FFP3 respirator masks
N95 respirators
Eye goggles (eye protection)
Face shield (full face protection)
No specific protection (surgical mask, gloves and apron)
Fig. 2. Specific protection adopted for laparoscopic surgery during COVID-19 outbreak. 
COVID, coronavirus disease.





Avoid maintenance with PARP inhibitors
Avoid maintenance with bevacizumab
No change
Others




(low burden of disease)
Laparoscopy+PDS




0% 20% 40% 60% 80% 100%
Fig. 3. Changing in the management of advanced stage ovarian cancer. 
COVID-19, coronavirus disease 2019; NACT, neoadjuvant chemotherapy; PDS, primary debulking surgery; PARP, poly(ADP-ribose) polymerase.
chemotherapy, regardless of disease burden (rating: 3.63), radiological-guided biopsy 
followed by neoadjuvant chemotherapy (rating: 2.75), and avoiding treatments (rating: 
1.60). Additionally, they suggested delaying chemotherapy and avoiding maintenance with 
bevacizumab in 14% and 10% of cases, respectively. Overall, 70% of the responders stated 
that they had not modified their approach to recurrent ovarian cancer (Supplementary 
Table 1). The most common recommendation was to avoid surgery in case of potentially 
resectable recurrent disease (13%) and to use neoadjuvant chemotherapy to delay secondary 
cytoreduction (17%). Responders stated that they had not modified their management 
of endometrial and cervical cancer in 70% and 75% of cases, respectively. Changing 
in endometrial cancer management included: delaying all treatments (14%), avoiding 
lymphadenectomy (8%), performing hysterectomy (with or without salpingo-oophorectomy) 
alone (8%), and avoiding surgery in favor of medical treatments (5%). Changing in cervical 
cancer management included: delaying all treatments (10%), avoiding surgery in favor of 
radiotherapy (10%), and avoiding lymphadenectomy in favor of sentinel node mapping (7%), 
and decreasing radicality intent/rate of surgery (6%). COVID-19 outbreak modified follow-up 
schedules (Fig. 4). On a scale between 0 (no impact) and 100 (maximum impact), responders 
rated that the impact of COVID-19 on quality of care for patients in follow-up was 42±5. The 
impact of COVID-19 on the inclusion of new patients in clinical trial was rated as 62±15. 
8/13https://ejgo.org https://doi.org/10.3802/jgo.2020.31.e92
Gynecology oncology during COVID-19 outbreak
Table 2. The impact of COVID-19 outbreak on the management of endometrial, and cervical cancer
Variables Frequency
Changing in management of endometrial cancer (multiple choice allowed)
Avoiding surgery (in favor of radiotherapy) 3.59%
Avoiding surgery (in favor of medical treatment) 5.38%
Only hysterectomy (no nodal dissection) 7.62%
Avoiding lymphadenectomy 8.07%




Changing in management of cervical cancer (multiple choice allowed)
Avoiding surgery (in favor of radiotherapy) 9.55%
Decreasing radicality of hysterectomy 5.91%











0% 20% 40% 60% 80% 100%
Fig. 4. Changing in follow-up schedules.
Physicians working in COVID-free HUBs were more likely to have fewer concerns in including 
patients into clinical trials than physician other centers (median rating: 38 vs. 61; p<0.001).
DISCUSSION
The widespread diffusion of COVID-19 requires preventive measures to reduce in-hospital 
viral transmission. Oncologic departments should be kept as COVID-free places. Drastic 
measures should be implemented to maintain an adequate standard of care for oncologic 
patients and to reduce the risk of contamination for health care providers and other patients. 
Recent guidelines suggested to minimize the number of clinical examinations and follow-
up visits and to reduce surgical procedures that may be associated with prolonged operative 
time, risk of significant complications and admission to intensive care units [11,12]. 
Postponing surgery in women with low-risk cancers has also been recommended, favoring 
medical treatment whenever possible [13]. To date, the risk for patients having chemotherapy 
is not clear. Whilst, the risk of for patients undergoing general anesthesia and extensive 
surgery seems to be high [14].
In order to save resources and avoid unnecessary exposure to infected patients, there is 
the need to redefine the timing of the surgery, scheduling interventions depending on 
patients' priority [15]. Our study highlights a marked heterogeneity in measures adopted 
by the Italian gynecologic community. Triage methods of patients who deserve to be 
admitted to hospitals differ among hospitals and regions. At present, there is a lack of 
COVID-19 testing guidelines through the Italian territory. Our survey highlighted that triage 
methods widely differ. Basically, anamnestic data represent the main method for triaging 
patients. SARS-CoV-2 rhino-pharyngeal swabs are performed only by a limited group of 
physicians. According to the results of our survey, gynecologists are more likely to test with 
swabs patients who are scheduled for surgery compared with those who are scheduled 
for chemotherapy or radiotherapy. Similarly, immunoglobulin testing is performed by 
less than 10% of physicians. However, we have to point out that to date, no validated 
immunoglobulin test exists.
Another point deserving attention is the impact of COVID-19 in the surgical practice. There 
are growing concerns on the use of laparoscopic surgery due to possible contamination of 
the staff working in the operative theatre [12,13]. An essential part of laparoscopic surgery is 
the establishment and maintenance of an artificial pneumoperitoneum, which is related to 
the risk of aerosol exposure into the operative room. Previous publications have suggested 
that laparoscopy could lead to aerosolization of viruses, but data on this way of transmission 
of COVID-19 are limited, at present. Nevertheless, erring on the side of safety would warrant 
treating the coronavirus as exhibiting similar aerosolization properties. Theoretically, SARS-
CoV-2 might infect the operative room staff during the laparoscopic procedures through 
aerosol formation. Consequently, viral particles released by trocar valves might infect health 
care providers. Approximately one out of four survey participants stated that they limited the 
use of laparoscopy, mostly in favor of the use of open procedures. Surprisingly, only 1 out of 
2 surgeons adopted specific protection during laparoscopic procedures. In particular, only 
35% of surgeons used respirator masks (including N95, FPP3, or other respirator masks that 
offer high level of protection). To date, there are no data promoting the use of open instead 
of minimally invasive surgery. The surgical teams have to identify the better approach for the 
patient. Surgeons have to perform procedures that guarantee their safety and provide the 
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best outcome for their patients. By this point of view, minimally invasive surgery is related to 
a short length of hospital stay and low complication rate than open surgery, and it should be 
preferred to reduce potential in-hospital contamination by COVID-19. In order to increase 
the adoption of minimally invasive procedures, adequate protection of the surgical team is 
needed [16].
Interestingly, several physicians stated that they changed they surgical plan during 
COVID-19 outbreak. The lack of medical sources/equipment (including the intensive care 
unit) and the possible risk of developing severe consequences for patients for patients 
harboring asymptomatic COVID-19 are the main reason to avoid extensive surgical 
procedure. Recently, the Fondazione IRCCS Istituto Nazionale dei Tumori, reported data of 5 
cancer patients affected by COVID-19 undergoing surgery at the beginning of the outbreak 
[11]. Among those 5 patients, 2 died in the early postoperative period; while other 2 patients 
needed prolonged hospitalization and intensive care unit admission [11].
There are 5 main weaknesses of the present paper. First, the majority of the questions 
contained in the survey are closed-ended questions, thus not capturing the full range of 
practice behaviors of responders. However, this method was chosen to avoid the answers' 
heterogeneity of open-text questions, that though yielding richer information can complicate 
analysis and interpretation of the results. Second, although we achieved a high response 
rate to the survey, our results may be affected by non-response bias. However, according to 
“continuum of resistance” model that place individuals who were interviewed during the 
first contact on 1 end of the continuum and nonparticipants on the other end. Basically, 
this model suggested that late-responders are expected to provide similar responses than 
non-respondents [17]. In our survey, no differences in term of baseline characteristics and 
responses were observed comparing early- and late-responders. Third, COVID-19 outbreak is 
a rapidly evolving situation. Therefore, attitudes and practice behaviors are changing rapidly, 
and the current practice registered at this moment might soon be changed across various 
centers. Fourth, we evaluated the situation in whole Italy; while COVID-19 had a different 
impact across the regions of Italy. Therefore, we can speculate that in some regions with a 
high incidence of COVID-19 (e.g., North of Italy), the impact of COVID-19 is higher than in 
other regions with low incidence of COVID-19 (e.g., South of Italy) [18]. Fifth, owing to the 
anonymous nature of the survey, we cannot evaluate how many responders belong from the 
same hospital, thus we cannot evaluate differences in responses from physician coming from 
the same center.
China and Italy have been the first and most affected countries worldwide. Gynecologists 
oncologists need to preserve the continuum of care of their patients, as the benefit of 
ensuring a well-delivered treatment plan outweighs the risk of COVID-19 infection. Results 
of this Italian survey suggest that gynecologic oncology departments have promptly 
set a proactive approach. Until now, evidence on the diffusion and management of 
COVID-19 in gynecologic oncologic patients is scant. This situation has led physicians to 
join forces [19-22]. Additionally, International cooperation is of paramount importance, 
as heavily affected nations (including Italy) can serve as an example to find out pathways 
to safely preserve health activity during the pandemic, worldwide. In conclusion, the 
present survey evaluated the impact of COVID-19 in gynecologic oncology practice. This 
survey highlighted a marked heterogeneity in the management of gynecologic oncologic 
patients during COVID-19 outbreak. Although about 70% of responders stated that they 
did not change their treatment paradigms, about 10%–15% of the responders have delayed 
10/13https://ejgo.org https://doi.org/10.3802/jgo.2020.31.e92
Gynecology oncology during COVID-19 outbreak
cancer treatment, and 20%–25% have performed less radical surgical procedures. National 
guidelines should be implemented to further promote the safety of patients and health 
care providers. Additionally, collaborative studies are needed to test the safety of different 
triage methods and to identify the best surgical treatment modality for our patients.
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